According to the current results, targeting TNF-α in the treatment of COVID-19 has a certain effect, but the current clinical evidence for adalimumab is still insufficient, and a large number of in vitro and in vivo experiments are still needed to verify whether adalimumab is truly effective against COVID-19. This evidence concerns the gene TNF and COVID-19.